DEVELOPMENTS IN THE TREATMENT OF RHEUMATOID ARTHRITIS: FOCUS ON SMALL MOLECULES
Introduction/Background
RA Is a Heterogeneous Complex Syndrome[a-d]
RA: Clinical Description and Sequelae
The Fate of Untreated RA
Immune and Inflammatory Responses: Pathogenesis of Synovitis Characteristic of RA
IL-6 in Inflammation, Immunity, and Disease
IL-6 and RA Pathogenesis
Many Cytokines and Growth Factors Converge on the JAK Signaling Pathway[a-c]
JAK-STAT Signaling in RA[a-c]
Focus on the JAK-STAT Pathway: Physiologic Roles
JAK-STAT Signaling and the Immune Response
The Biological Significance of Signaling Through Different JAK Combinations
The Human Canonical Model of JAK-STAT Signaling
Dysregulated JAK-STAT Signaling and RA Pathogenesis
Elevated STAT3 Expression in Patients With Early RA
The JAK-STAT Pathway and RA Pharmacotherapeutics
Tofacitinib JAK 1/3 Inhibitor: Clinical Trials in RA
Tofacitinib or ADA vs PBO in RA: Results From ORAL Standard
Tofacitinib JAK 1/3 Inhibitor: Clinical Trial Results From ORAL Start
Proportion of TNF-IR, DMARD-IR, and MTX-Naive Patients With ACR50 Response in Tofacitinib Trials
Baricitinib: Key Studies in RA Phase 3 Program and Their Characteristics
Baricitinib JAK 1/2 Inhibitor: RA-BEAM Results Overview
RA-BEAM Phase 3: ACR Outcomes at Weeks 12 and 24
PROs: RA-BEAM Phase 3 Trial of Baricitinib
Baricitinib JAK 1/2 Inhibitor: RA-BUILD Results Overview
RA-BUILD Phase 3: PROs at Week 24 Baricitinib in csDMARD-IR and bDMARD-Naive Patients With Moderate to Severe RA
RA-BEACON: Baricitinib in RA Patients With an Inadequate Response to TNF-ɑ Inhibitors
Results From the Baricitinib LTE RA-BEYOND Trial
Filgotinib JAK 1 Inhibitor: Clinical Trial Results in RA
DARWIN 1 Phase 2: ACR Outcomes at Week 12 in MTX-IR: Filgotinib + MTX in Patients With Active RA
DARWIN 2 Phase 2: ACR Outcomes at Week 12 in MTX-IR: Filgotinib Monotherapy in Patients With Active RA
RA Pharmacotherapeutics: Other Targets and Agents
Summary and Conclusions
Abbreviations
Abbreviations (cont)
Abbreviations (cont)
Abbreviations (cont)